Breyanzi denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for breyanzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Breyanzi: Quantity Limits

Breyanzi (lisocabtagene maraleucel) is a one-time CAR-T cell therapy infusion — it is manufactured from your own T-cells and administered as a single treatment course. A quantity-limits denial in this context almost always reflects a formulary or utilization management rule applied incorrectly to a therapy that, by its clinical and manufacturing design, is not subject to refill or repeat dosing in the conventional sense.

This denial type is among the most straightforward to challenge for CAR-T therapies, because the quantity-limit logic that applies to conventional medications does not translate to a patient-specific cell therapy with a defined single-course administration protocol.

## Why This Denial Is Appealable

If Cigna's quantity-limit denial is based on a per-year or per-course limit that would effectively deny the single authorized course of Breyanzi, the denial conflicts with both the FDA-approved prescribing information and fundamental clinical reality. An IRO reviewing a quantity-limit denial for a CAR-T therapy will scrutinize whether the limit serves any clinical or cost-management purpose that doesn't amount to a de facto denial of a covered benefit.

If the denial relates to a retreatment scenario — a second course of CAR-T therapy — the appeal should focus on the oncologist's documented clinical rationale and any emerging evidence supporting retreatment in your specific situation.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File within 180 days of denial. Expedited review (72-hour decision) is available if delay poses clinical risk.
• External review (ACA §2719): Available after exhausting internal appeals, generally within 4 months. An IRO with oncology expertise evaluates whether the quantity limit was appropriately applied to a CAR-T cell therapy. Binding on Cigna.
• Expedited external review: Available for serious/life-threatening conditions — request in writing if disease status warrants.

## Documentation to Gather

• FDA prescribing information for Breyanzi — the dosing and administration section, which describes Breyanzi as a single-infusion treatment; attach as an exhibit to demonstrate that the quantity-limit logic does not apply
• Oncologist letter explaining Breyanzi's single-course administration protocol and, if this is a retreatment request, the clinical rationale for a second course
• Cigna's quantity-limit policy for Breyanzi / CAR-T — obtain the version in effect at denial; identify the specific limit that triggered the denial
• Denial letter — note the exact quantity cited (e.g., "1 unit per lifetime" vs. "1 per year") to confirm whether the limit was misapplied or whether a retreatment exception is needed
• Treatment history showing the prior course of Breyanzi (if retreatment) with dates, response, and current disease status

## Criteria-Mapping Structure

| Quantity-Limit Basis | Your Rebuttal | |---|---| | Limit as applied to single-course CAR-T | [FDA label description of single-infusion protocol; oncologist confirmation that only one course is being requested] | | Retreatment request (if applicable) | [Prior treatment date; disease response; current status; oncologist's clinical rationale for second course] | | Policy language on CAR-T quantity limits | [Quote policy; argue the limit was not designed for or cannot be applied to this therapy type] | | Clinical guideline support | [Reference relevant hematology guideline organization by name without quoting statistics] |

For an initial single-course request, a quantity-limits denial for Breyanzi is typically resolved quickly once the appeal explains that a one-time cell therapy is not subject to the refill-based logic the limit was designed to address.